ALHEMO (concizumab)
TherapyNovo Nordisk
ALHEMO (concizumab) from Novo Nordisk is a therapy engineered for use in hemophilia settings, including patients with inhibitors.
Approvals
1
Indications
1
Biomarkers
1
Mapped tests
1
Where this therapy is approved with a companion diagnostic
Each row represents a defined combination of indication, biomarker criteria, and ALHEMO. Select a testing pathway to see the eligible companion diagnostic tests.
Indication-specific approvals
Approvals where ALHEMO is tied to a specific indication and biomarker definition.
| Indication | Biomarker criteria | Notes | |
|---|---|---|---|
Hemophilia A patients with or without factor VIII inhibitors and Hemophilia B patients with or without IX inhibitors Non-cancer · Blood | Concizumab
| View testing pathway → |
Tumor-agnostic approvals
Approvals defined at the solid tumor level where biomarker criteria determine eligibility for ALHEMO.
No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.
Tests used in these approvals
These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering ALHEMO for eligible patients.
Test
ConcizuTrace ELISA
Randox Laboratories Ltd.
Method
ELISA
Specimen
Plasma
1 approvalView test profile →